# A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06417008/  
OnCo record `nct06417008` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing HS-20117 in non-small-cell lung cancer, now recruiting.

## Summary

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT06417008, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer. Planned enrolment is 1080 participants (estimated). The study started in 2024-05-28 and primary completion is expected in 2026-06-01. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06417008
- Phase: 2/3
- Setting: A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Sponsor: Hansoh BioMedical R&D
- Enrolled: 1080

## Sources

- ClinicalTrials.gov NCT06417008: https://clinicaltrials.gov/study/NCT06417008

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [HS-20117](https://onco.cc/drugs/hs-20117/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06417008.json